Latest news with #NasdaqCM
Malaysian Reserve
4 days ago
- Business
- Malaysian Reserve
QUANTUM COMPUTING INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quantum Computing Inc.
NEW YORK and NEW ORLEANS, July 11, 2025 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ('KSF'), announces that KSF has commenced an investigation into Quantum Computing Inc. (NasdaqCM: QUBT). On January 16, 2025, Capybara Research reported a myriad of allegations against the Company including that it had overstated its ties to NASA and fabricated revenues through multiple related-party transactions, particularly with Quad M and millionways; that its products were fake, citing comments by former QCI personnel; and that it was pumping its stock price with false and misleading press releases, citing discussions with its former employees, associates and prime contractors, and NASA personnel. Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws, which remains ongoing. KSF's investigation is focusing on whether Quantum's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Quantum shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services To learn more about KSF, you may visit Contact:Kahn Swick & Foti, LLCLewis Kahn, Managing Poydras St., Suite 960New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
Business Wire
7 days ago
- Business
- Business Wire
PB BANKSHARES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PB Bankshares, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of PB Bankshares, Inc. (NasdaqCM: PBBK) to Norwood Financial Corp (NasdaqGM: NWFL). Under the terms of the proposed transaction, shareholders of PB Bankshares will have the option to elect to receive either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share of PB Bankshares they own, subject to proration to ensure that, in the aggregate, 80% of the transaction consideration will be paid in the form of Norwood common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
10-06-2025
- Business
- Business Wire
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Elevation Oncology, Inc. (NasdaqCM: ELEV) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
09-06-2025
- Business
- Business Wire
PROVIDENT BANCORP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provident Bancorp, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Provident Bancorp, Inc. (NasdaqCM: PVBC) to NB Bancorp, Inc. (NasdaqCM: NBBK). Under the terms of the proposed transaction, shareholders of Provident can elect to receive either: (i) 0.691 shares of NB Bancorp common stock or (ii) $13.00 in cash, for each share of Provident that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
05-06-2025
- Business
- Yahoo
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ('MEDIROM' or the 'Company'), today announced that on June 4, 2025, it received a written notification from The Nasdaq Stock Market LLC ('Nasdaq') notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On February 27, 2025, the Company received notice from Nasdaq that it was not in compliance with the minimum bid price requirement, which requires listed securities to maintain a minimum closing bid price of $1.00 per share. To regain compliance, the Company's American Depositary Shares, representing common shares of the Company ('ADSs'), were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company was provided 180 calendar days through August 26, 2025, to regain compliance. On June 4, 2025, Nasdaq confirmed that for the last 10 consecutive business days, from May 20, 2025 to June 3, 2025, the closing bid price of the Company's ADSs had been $1.00 per share or greater. Accordingly, Nasdaq informed the Company that the Company has regained compliance with Nasdaq Listing rule 5550(a)(2) and that this matter is now closed. About MEDIROM Healthcare Technologies a holistic healthcare company, operates over 300 wellness salons across Japan, being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called 'Lav®', which is developed by the Company. MEDIROM also entered the device business in 2020 and has developed a smart tracker, the 'MOTHER Bracelet®'. In 2023, MEDIROM launched REMONY, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM aims to leverage its diverse portfolio of health-related products and services to collect and manage healthcare data from users and customers, positioning itself as a leader in healthcare big data in Japan. For more information, visit Forward-Looking StatementsCertain statements included in this press release relating to MEDIROM are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may include projections and estimates concerning MEDIROM's possible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'design,' 'target,' 'aim,' 'expect,' 'could,' 'intend,' 'plan,' 'anticipate,' 'estimate,' 'believe,' 'continue,' 'predict,' 'project,' 'potential,' 'goal' or other words that convey the uncertainty of future events or outcomes. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These forward-looking statements include, but are not limited to, forecasts of financial and performance metrics (including key performance indicators), and projections of market size and opportunity. These statements are based on various assumptions and on the current expectations of MEDIROM and its management and are not predictions of actual performance. While MEDIROM's management considers these assumptions and expectations to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond MEDIROM's control. If the risks materialize or MEDIROM's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future. ContactInvestor Relations Teamir@ in to access your portfolio
